Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis.
Bleomycin
Interleukin-6
Mesenchymal stromal cells
Pulmonary fibrosis
Regulatory T cells
Serum-free
Transforming growth factor-β
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
16 09 2021
16 09 2021
Historique:
received:
26
05
2021
accepted:
27
08
2021
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Mesenchymal stromal cells (MSCs) are a potential therapeutic tool for pulmonary fibrosis. However, ex vivo MSC expansion using serum poses risks of harmful immune responses or unknown pathogen infections in the recipients. Therefore, MSCs cultured in serum-free media (SF-MSCs) are ideal for clinical settings; however, their efficacy in pulmonary fibrosis is unknown. Here, we investigated the effects of SF-MSCs on bleomycin-induced pulmonary inflammation and fibrosis compared to those of MSCs cultured in serum-containing media (S-MSCs). SF-MSCs and S-MSCs were characterized in vitro using RNA sequence analysis. The in vivo kinetics and efficacy of SF-MSC therapy were investigated using a murine model of bleomycin-induced pulmonary fibrosis. For normally distributed data, Student's t test and one-way repeated measures analysis of variance followed by post hoc Tukey's test were used for comparison between two groups and multiple groups, respectively. For non-normally distributed data, Kruskal-Wallis and Mann-Whitney U tests were used for comparison between groups, using e Bonferroni's correction for multiple comparisons. All tests were two-sided, and P < 0.05 was considered statistically significant. Serum-free media promoted human bone marrow-derived MSC expansion and improved lung engraftment of intravenously administered MSCs in recipient mice. SF-MSCs inhibited the reduction in serum transforming growth factor-β1 and the increase of interleukin-6 in both the serum and the bronchoalveolar lavage fluid during bleomycin-induced pulmonary fibrosis. SF-MSC administration increased the numbers of regulatory T cells (Tregs) in the blood and lungs more strongly than in S-MSC administration. Furthermore, SF-MSCs demonstrated enhanced antifibrotic effects on bleomycin-induced pulmonary fibrosis, which were diminished by antibody-mediated Treg depletion. SF-MSCs significantly suppressed BLM-induced pulmonary inflammation and fibrosis through enhanced induction of Tregs into the lungs and corrected the dysregulated cytokine balance. Therefore, SF-MSCs could be a useful tool for preventing pulmonary fibrosis progression without the demerits of serum use.
Sections du résumé
BACKGROUND
Mesenchymal stromal cells (MSCs) are a potential therapeutic tool for pulmonary fibrosis. However, ex vivo MSC expansion using serum poses risks of harmful immune responses or unknown pathogen infections in the recipients. Therefore, MSCs cultured in serum-free media (SF-MSCs) are ideal for clinical settings; however, their efficacy in pulmonary fibrosis is unknown. Here, we investigated the effects of SF-MSCs on bleomycin-induced pulmonary inflammation and fibrosis compared to those of MSCs cultured in serum-containing media (S-MSCs).
METHODS
SF-MSCs and S-MSCs were characterized in vitro using RNA sequence analysis. The in vivo kinetics and efficacy of SF-MSC therapy were investigated using a murine model of bleomycin-induced pulmonary fibrosis. For normally distributed data, Student's t test and one-way repeated measures analysis of variance followed by post hoc Tukey's test were used for comparison between two groups and multiple groups, respectively. For non-normally distributed data, Kruskal-Wallis and Mann-Whitney U tests were used for comparison between groups, using e Bonferroni's correction for multiple comparisons. All tests were two-sided, and P < 0.05 was considered statistically significant.
RESULTS
Serum-free media promoted human bone marrow-derived MSC expansion and improved lung engraftment of intravenously administered MSCs in recipient mice. SF-MSCs inhibited the reduction in serum transforming growth factor-β1 and the increase of interleukin-6 in both the serum and the bronchoalveolar lavage fluid during bleomycin-induced pulmonary fibrosis. SF-MSC administration increased the numbers of regulatory T cells (Tregs) in the blood and lungs more strongly than in S-MSC administration. Furthermore, SF-MSCs demonstrated enhanced antifibrotic effects on bleomycin-induced pulmonary fibrosis, which were diminished by antibody-mediated Treg depletion.
CONCLUSIONS
SF-MSCs significantly suppressed BLM-induced pulmonary inflammation and fibrosis through enhanced induction of Tregs into the lungs and corrected the dysregulated cytokine balance. Therefore, SF-MSCs could be a useful tool for preventing pulmonary fibrosis progression without the demerits of serum use.
Identifiants
pubmed: 34530920
doi: 10.1186/s13287-021-02574-5
pii: 10.1186/s13287-021-02574-5
pmc: PMC8444523
doi:
Substances chimiques
Culture Media, Serum-Free
0
Bleomycin
11056-06-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
506Informations de copyright
© 2021. The Author(s).
Références
Respir Res. 2018 Apr 24;19(1):71
pubmed: 29690905
Stem Cells Transl Med. 2020 Jan;9(1):17-27
pubmed: 31804767
BMJ. 2021 Feb 11;372:n433
pubmed: 33574097
PLoS One. 2013 May 07;8(5):e63432
pubmed: 23667616
Sci Rep. 2017 Oct 27;7(1):14272
pubmed: 29079731
Am J Respir Cell Mol Biol. 2017 May;56(5):667-679
pubmed: 28459387
Nat Commun. 2020 Jun 3;11(1):2795
pubmed: 32493933
J Clin Invest. 2009 Oct;119(10):2898-913
pubmed: 19770521
Gastroenterol Hepatol Bed Bench. 2020 Fall;13(4):388-392
pubmed: 33244382
Nat Biotechnol. 2014 Mar;32(3):252-60
pubmed: 24561556
Immunobiology. 2013 Feb;218(2):245-54
pubmed: 22739236
Cell Mol Immunol. 2017 May;14(5):423-431
pubmed: 26435067
Theranostics. 2017 Jan 1;7(1):106-116
pubmed: 28042320
Cell Transplant. 2012;21(9):1997-2008
pubmed: 22469297
Nature. 2006 May 11;441(7090):235-8
pubmed: 16648838
Stem Cells Transl Med. 2020 Jan;9(1):6-16
pubmed: 31613055
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
Cell Physiol Biochem. 2014;33(3):569-80
pubmed: 24603109
J Immunol. 2020 May 1;204(9):2429-2438
pubmed: 32213566
Int J Hematol. 2016 Feb;103(2):243-50
pubmed: 26608364
Biochimie. 2021 Jun;185:9-21
pubmed: 33711361
Stem Cells Transl Med. 2021 May;10(5):660-673
pubmed: 33400390
Am J Respir Cell Mol Biol. 2018 Feb;58(2):216-231
pubmed: 28915065
Cell Prolif. 2013 Dec;46(6):608-27
pubmed: 24118248
Allergy. 2020 Apr;75(4):882-891
pubmed: 31750952
Anaesth Crit Care Pain Med. 2020 Feb;39(1):35-44
pubmed: 31374365
Intensive Care Med Exp. 2020 Feb 5;8(1):8
pubmed: 32025852
Crit Care Med. 2017 Feb;45(2):e202-e212
pubmed: 27861182
Front Bioeng Biotechnol. 2020 Jun 26;8:586
pubmed: 32671030
Cell Biol Int. 2012 Aug 1;36(8):747-53
pubmed: 22352320
Int J Mol Sci. 2021 Apr 17;22(8):
pubmed: 33920714
Cytotherapy. 2017 Feb;19(2):155-169
pubmed: 28017599
Front Cell Dev Biol. 2019 Nov 15;7:285
pubmed: 31799252
Cell Stem Cell. 2012 May 4;10(5):544-55
pubmed: 22542159
Cell Commun Signal. 2011 May 14;9:12
pubmed: 21569606
Circ Res. 2009 Feb 13;104(3):398-402
pubmed: 19096027
Pulm Pharmacol Ther. 2016 Oct;40:95-103
pubmed: 27481628
J Clin Med. 2020 Mar 03;9(3):
pubmed: 32138309
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Stem Cells. 2005 Oct;23(9):1357-66
pubmed: 16081661
Mol Med Rep. 2015 Apr;11(4):2831-7
pubmed: 25514921
J Cell Physiol. 2021 Apr;236(4):2829-2839
pubmed: 32926425
J Clin Invest. 1997 Aug 15;100(4):768-76
pubmed: 9259574
Am J Respir Crit Care Med. 2017 Aug 1;196(3):266-273
pubmed: 28306336
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Cell Physiol Biochem. 2015;36(2):697-711
pubmed: 25998889
Front Immunol. 2018 Mar 23;9:585
pubmed: 29662491
Stem Cell Res Ther. 2021 Mar 23;12(1):203
pubmed: 33757592
Mucosal Immunol. 2014 Nov;7(6):1440-51
pubmed: 24850425
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
Expert Opin Ther Targets. 2015;19(8):1091-103
pubmed: 25881491
N Biotechnol. 2015 Jan 25;32(1):199-211
pubmed: 24929129
Proc Am Thorac Soc. 2012 Jul;9(3):130-6
pubmed: 22802287
Stem Cells Transl Med. 2015 Dec;4(12):1500-10
pubmed: 26494779
Crit Care Med. 2014 Jul;42(7):e510-24
pubmed: 24633189
PLoS One. 2009 Sep 22;4(9):e7119
pubmed: 19771171
Front Immunol. 2012 Sep 26;3:297
pubmed: 23056000
Respir Res. 2015 Aug 20;16:99
pubmed: 26289430
Stem Cell Investig. 2019 Aug 16;6:22
pubmed: 31559309
Stem Cells Transl Med. 2018 Dec;7(12):893-905
pubmed: 30269426
Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7568-7572
pubmed: 31539148